Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
Standard
Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. / Rawstron, Andy C; Orfao, Alberto; Beksac, Meral; Bezdickova, Ludmila; Brooimans, Rik A; Bumbea, Horia; Dalva, Klara; Fuhler, Gwenny; Gratama, Jan; Hose, Dirk; Kovarova, Lucie; Lioznov, Michael; Mateo, Gema; Morilla, Ricardo; Mylin, Anne K; Omedé, Paola; Pellat-Deceunynck, Catherine; Martin, Perez Andres; Petrucci, Maria; Ruggeri, Marina; Rymkiewicz, Grzegorz; Schmitz, Alexander; Schreder, Martin; Seynaeve, Carine; Spacek, Martin; Tute, de; Ruth, M; Els, Van Valckenborgh; Weston-Bell, Nicky; Owen, Roger G; Miguel, San; Jesús, F; Sonneveld, Pieter; Johnsen, Hans E.
in: HAEMATOLOGICA, Jahrgang 93, Nr. 3, 3, 2008, S. 431-438.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.
AU - Rawstron, Andy C
AU - Orfao, Alberto
AU - Beksac, Meral
AU - Bezdickova, Ludmila
AU - Brooimans, Rik A
AU - Bumbea, Horia
AU - Dalva, Klara
AU - Fuhler, Gwenny
AU - Gratama, Jan
AU - Hose, Dirk
AU - Kovarova, Lucie
AU - Lioznov, Michael
AU - Mateo, Gema
AU - Morilla, Ricardo
AU - Mylin, Anne K
AU - Omedé, Paola
AU - Pellat-Deceunynck, Catherine
AU - Martin, Perez Andres
AU - Petrucci, Maria
AU - Ruggeri, Marina
AU - Rymkiewicz, Grzegorz
AU - Schmitz, Alexander
AU - Schreder, Martin
AU - Seynaeve, Carine
AU - Spacek, Martin
AU - Tute, de
AU - Ruth, M
AU - Els, Van Valckenborgh
AU - Weston-Bell, Nicky
AU - Owen, Roger G
AU - Miguel, San
AU - Jesús, F
AU - Sonneveld, Pieter
AU - Johnsen, Hans E
PY - 2008
Y1 - 2008
N2 - The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases.
AB - The European Myeloma Network (EMN) organized two flow cytometry workshops. The first aimed to identify specific indications for flow cytometry in patients with monoclonal gammopathies, and consensus technical approaches through a questionnaire-based review of current practice in participating laboratories. The second aimed to resolve outstanding technical issues and develop a consensus approach to analysis of plasma cells. The primary clinical applications identified were: differential diagnosis of neoplastic plasma cell disorders from reactive plasmacytosis; identifying risk of progression in patients with MGUS and detecting minimal residual disease. A range of technical recommendations were identified, including: 1) CD38, CD138 and CD45 should all be included in at least one tube for plasma cell identification and enumeration. The primary gate should be based on CD38 vs. CD138 expression; 2) after treatment, clonality assessment is only likely to be informative when combined with immunophenotype to detect abnormal cells. Flow cytometry is suitable for demonstrating a stringent complete remission; 3) for detection of abnormal plasma cells, a minimal panel should include CD19 and CD56. A preferred panel would also include CD20, CD117, CD28 and CD27; 4) discrepancies between the percentage of plasma cells detected by flow cytometry and morphology are primarily related to sample quality and it is, therefore, important to determine that marrow elements are present in follow-up samples, particularly normal plasma cells in MRD negative cases.
U2 - 10.3324/haematol.11080
DO - 10.3324/haematol.11080
M3 - SCORING: Zeitschriftenaufsatz
VL - 93
SP - 431
EP - 438
JO - HAEMATOLOGICA
JF - HAEMATOLOGICA
SN - 0390-6078
IS - 3
M1 - 3
ER -
